These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 24927407)

  • 1. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.
    Ehninger A; Kramer M; Röllig C; Thiede C; Bornhäuser M; von Bonin M; Wermke M; Feldmann A; Bachmann M; Ehninger G; Oelschlägel U
    Blood Cancer J; 2014 Jun; 4(6):e218. PubMed ID: 24927407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression.
    Soare DS; Radu E; Dumitru I; Popov VM; Bumbea H; Vlădăreanu AM
    J Cell Mol Med; 2020 Jul; 24(13):7675-7679. PubMed ID: 32460405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
    Falini B; Sportoletti P; Brunetti L; Martelli MP
    Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
    Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the
    Soare DS; Radu E; Dumitru I; Vlădăreanu AM; Bumbea H
    Leuk Lymphoma; 2021 Nov; 62(11):2716-2726. PubMed ID: 34034609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.
    Zeng Z; Roobrouck A; Deschamps G; Bonnevaux H; Guerif S; De Brabandere V; Amara C; Dejonckheere E; Virone-Oddos A; Chiron M; Konopleva M; Dullaers M
    Blood Adv; 2024 May; 8(9):2059-2073. PubMed ID: 38266153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
    Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
    Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations.
    Riccioni R; Pelosi E; Riti V; Castelli G; Lo-Coco F; Testa U
    Br J Haematol; 2011 Apr; 153(1):33-42. PubMed ID: 21332708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
    Pollard JA; Alonzo TA; Gerbing RB; Woods WG; Lange BJ; Sweetser DA; Radich JP; Bernstein ID; Meshinchi S
    Blood; 2006 Oct; 108(8):2764-9. PubMed ID: 16809615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
    Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation.
    De Propris MS; Raponi S; Diverio D; Milani ML; Meloni G; Falini B; Foà R; Guarini A
    Haematologica; 2011 Oct; 96(10):1548-51. PubMed ID: 21791474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.
    Bras AE; de Haas V; van Stigt A; Jongen-Lavrencic M; Beverloo HB; Te Marvelde JG; Zwaan CM; van Dongen JJM; Leusen JHW; van der Velden VHJ
    Cytometry B Clin Cytom; 2019 Mar; 96(2):134-142. PubMed ID: 30450744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape.
    Sun S; Zou H; Li L; Liu Q; Ding N; Zeng L; Li H; Mao S
    Int J Pharm; 2019 Sep; 568():118518. PubMed ID: 31319147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
    Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
    Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
    Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
    Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
    Pizzitola I; Anjos-Afonso F; Rouault-Pierre K; Lassailly F; Tettamanti S; Spinelli O; Biondi A; Biagi E; Bonnet D
    Leukemia; 2014 Aug; 28(8):1596-605. PubMed ID: 24504024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.
    Riccioni R; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Ottone T; Foà R; Testa U
    Br J Haematol; 2009 Feb; 144(3):376-87. PubMed ID: 19036083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.